Interesting paper on mTOR inhibitors as tested in c.elegans:
Characterization of Effects of mTOR Inhibitors on Aging in Caenorhabditis elegans
Pharmacological inhibition of the mechanistic target of rapamycin (mTOR) signaling pathway with rapamycin can extend lifespan in several organisms. Although this includes the nematode Caenorhabditis elegans , effects in this species are relatively weak and sometimes difficult to reproduce. Here we test effects of drug dosage and timing of delivery to establish the upper limits of its capacity to extend life, and investigate drug effects on age-related pathology and causes of mortality. Liposome-mediated rapamycin treatment throughout adulthood showed a dose-dependent effect, causing a maximal 21.9% increase in mean lifespan, but shortening of lifespan at the highest dose, suggesting drug toxicity. Rapamycin treatment of larvae delayed development, weakly reduced fertility and modestly extended lifespan. By contrast, treatment initiated later in life robustly increased lifespan, even from Day 16 (or ~70 years in human terms). The rapalog temsirolimus extended lifespan similarly to rapamycin, but effects of everolimus were weaker. As in mouse, rapamycin had mixed effects on age-related pathologies, inhibiting one (uterine tumor growth) but not several others, suggesting a segmental antigeroid effect. These findings should usefully inform future experimental studies with rapamycin and rapalogs in C. elegans .
1 Like
Karel1
#22
https://spotify.localizer.co/uploads/default/original/3X/2/6/26245078ffb07fd4dc54bcbe1364148c0eacfa86.png
@Krister_Kauppi can you explain why sirolimus shows a negative effect on both healthspan and lifespan in this table. My guess dose way too high???
Thanks
Started with Mobile today - after the lab work was done they sent along the scrip and I was able to order Rapacan from the Amazon pharmacy.
I start today. 
2 Likes
Karel1
#24
Crowdfunding seems great if it is to test substances that are well known and not patentable.
The product/diet etc. should be affordable for at least 80% of the population.
This seems to be relatively news substances based on chemical modifications of known substances which will result in high cost patented drugs and extreme profits for the discoverers.
Why not issue shares and let everyone who invests benefit instead of just the persons that run a farm of C. Elegans worms on a disc. Some persons in this forum can easily spend 25 or 100K without even notice it… I want longer healthspan and lifespan for the masses!
1 Like
@Karel1 I have been in contact with different labs around that in some labs they see good benefits of rapamycin and in other ones none. The latest person I talked to this week was with the researcher David Gem and they have had challenges with getting rapamycin to work in worms. Also the ITP for worms CIPT had this issue. The company Epiterna and also other labs. In this clip Mitchell Lee, the CEO of Ora Biomedical, talks about why Rapamycin and other rapalogs are not working as expected. The problem is due to problems with crystallization on higher doses but I think there might be some way to get rapamycin to work. This is why I’m trying to figure out some way for it and talk to different labs.
It’s good that you lift up the investment opportunities and I have started to think more and more around this. One big problem with making this project an investment project is that there would not be any good incentives to make this data public. I feel it’s very important that we provide this basic data to the public. It can not be hidden. But one potential way that I may add as a bonus to this project is that depending on the amount people sponsor the bigger pre-investing amount they will have around these compounds when Rapamycin Longevity Lab starts to develop cocktails around these. For example, let’s say you sponsor 1000$ then you will be able to pre-invest $1000 before everyone else on each new cocktail that the Rapamycin Longevity Lab develops based on these compounds. What do you think about that?
1 Like
amuser
#26
The below leads one to believe all 600 are funded by 50K, when in fact it covers only a bit over half the cost.
Suggest updating that 601 to 300.
1 Like
